Molecular targeted therapy of nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2018.01.009

Abstract

Abstract: At present, the treatment of nonsmall cell lung cancer (NSCLC) has entered the era of targeted therapy, and small molecule tyrosine kinase inhibitors are typical representatives, which have clear molecular targets and remarkable effects. But many patients without mutations are not able to benefit from them. Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment. Inhibitors such as programmed cell death1 and programmed cell deathligand 1 have shown great applied potential in a series of clinical trials of NSCLC.

Key words: Carcinoma, nonsmallcell lung, Immunotoxins, Therapeutic uses

Nan Zhaodi, Chen Shaoshui. Molecular targeted therapy of nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(1): 39-.

References

［1］ Ma W, Xu M, Liu Y, et al. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced nonsmallcell lung cancer: a metaanalysis of fifteen phase Ⅱ/Ⅲ randomized trials［J］. Int J Cancer, 2015, 137(2): 409419. DOI: 10.1002/ijc.29377. ［2］ Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of nonsmall cell lung cancerrecent advances and future perspectives［J］. Int J Cancer, 2016, 138(11): 25492561. DOI: 10.1002/ijc.29915. ［3］ FrieseHamim M, Bladt F, Locatelli G, et al .The selective cMet inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant cMet activation in NSCLC models［J］. Am J Cancer Res, 2017, 7(4): 962972. ［4］ Jnne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitorresistant nonsmallcell lung cancer［J］. N Engl J Med, 2015, 372(18): 16891699. DOI: 10.1056/NEJMoa1411817. ［5］ Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Metpositive advanced nonsmallcell lung cancer (AURA2): a multicentre, openlabel, singlearm, phase 2 study［J］. Lancet Oncol, 2016, 17(12): 16431652. DOI: 10.1016/S14702045(16)305083. ［6］ Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinumpemetrexed in EGFR T790Mpositive lung cancer［J］. N Engl J Med, 2017, 376(7): 629640. DOI: 10.1056/NEJMoa1612674. ［7］ Park K, Lee JS, Han JY, et al. 130O: efficacy and safety of BI 1482694 (HM61713), an EGFR mutantspecific inhibitor, in T790Mpositive NSCLC at the recommended phase Ⅱ dose［J］. J Thorac Oncol, 2016, 11 Suppl 4: S113. DOI: 10.1016/S15560864(16)30243X. ［8］ Xu X, Mao L, Xu W, et al. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790Minduced resistance in animal models and lung cancer patients［J］. Mol Cancer Ther, 2016, 15(11): 25862597. DOI: 10.1158/15357163.MCT160281. ［9］ Xu X. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790Minduced resistance［J］. Chin J Cancer, 2015, 34(7): 285287. DOI: 10.1186/s4088001500293. ［10］ Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced nonsmall cell lung cancer harboring EGFR T790M［J］. Nat Med, 2015, 21(6): 560562. DOI: 10.1038/nm.3854. ［11］ Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutantselective allosteric inhibitors［J］. Nature, 2016, 534(7605): 129132. DOI: 10.1038/nature17960. ［12］ Liu YT, Shi YK, Hao XZ, et al. Analysis of clinicopathological features of the echinoderm microtubuleassociated proteinlike4anaplastic lymphoma kinase fusion gene in Chinese patients with advanced nonsmallcell lung cancer［J］. Thorac Cancer, 2014, 5(3): 255260. DOI: 10.1111/17597714.12101. ［13］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25): 23852394. DOI: 10.1056/NEJMoa1214886. ［14］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 21672177. DOI: 10.1056/NEJMoa1408440. ［15］ Sun HY, Ji FQ. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK［J］. Biochem Biophys Res Commun, 2012, 423(2): 319324. DOI: 10.1016/j.bbrc.2012.05.120. ［16］ Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALKrearranged nonsmallcell lung cancer (ASCEND1): updated results from the multicentre, openlabel, phase 1 trial［J］. Lancet Oncol, 2016, 17(4): 452463. DOI: 10.1016/S14702045(15)006142. ［17］ Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase Ⅱ study of wholebody and intracranial activity with ceritinib in patients with ALKrearranged nonsmallcell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND2［J］. J Clin Oncol, 2016, 34(24): 28662873. DOI: 10.1200/JCO.2015.65.5936. ［18］ Soria JC, Tan DSW, Chiari R, et al. Firstline ceritinib versus platinumbased chemotherapy in advanced ALKrearranged nonsmallcell lung cancer (ASCEND4): a randomised, openlabel, phase 3 study［J］. Lancet, 2017, 389(10072): 917929. DOI: 10.1016/S01406736(17)30123X. ［19］ Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALKpositive, crizotinibresistant, nonsmallcell lung cancer: a singlegroup, multicentre, phase 2 trial［J］. Lancet Oncol, 2016, 17(2): 234242. DOI: 10.1016/S14702045(15)00488X. ［20］ Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinibrefractory ALKrearranged nonsmallcell lung cancer: a phase Ⅱ global study［J］. J Clin Oncol, 2016, 34(7): 661668. DOI: 10.1200/JCO.2015.63.9443. ［21］ Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALKpositive nonsmallcell lung cancer (JALEX): an openlabel, randomised phase 3 trial［J］. Lancet, 2017, 390(10089): 2939. DOI: 10.1016/S01406736(17)305652. ［22］ Perez CA, Velez M, Raez LE, et al. Overcoming the resistance to crizotinib in patients with nonsmall cell lung cancer harboring EML4/ALK translocation［J］. Lung Cancer, 2014, 84(2): 110115. DOI: 10.1016/j.lungcan.2014.02.001. ［23］ Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALKrearranged nonsmallcell lung cancer and other malignancies: a singlearm, openlabel, phase 1/2 trial［J］. Lancet Oncol, 2016, 17(12): 16831696. DOI: 10.1016/S14702045(16)303928. ［24］ Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinibrefractory anaplastic lymphoma kinasepositive nonsmallcell lung cancer: a randomized, multicenter phase Ⅱ trial［J］. J Clin Oncol, 2017, 35(22): 24902498. DOI: 10.1200/JCO.2016.71.5904. ［25］ Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rdgeneration ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib［J］. Eur J Med Chem, 2017, 134: 348356. DOI: 10.1016/j.ejmech.2017.04.032. ［26］ Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, doubleblind, placebocontrolled, multicenter, phase Ⅲ study of firstline carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2015, 33(19): 21972204. DOI: 10.1200/JCO.2014.59.4424. ［27］ Ou SH, Tan J, Yen Y, et al. ROS1 as a ′druggable′ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway［J］. Expert Rev Anticancer Ther, 2012, 12(4): 447456. DOI: 10.1586/ERA.12.17. ［28］ Bauer TM, Schuler M, Berardi R, et al. MINI01.03 phase (Ph) Ⅰ study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients with advanced cMET+ NSCLC topic: medical oncology［J］. J Thorac Oncol, 2016, 11(11S): S257S258. DOI: 10.1016/j.jtho.2016.09.018. ［29］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 16271639. DOI: 10.1056/NEJMoa1507643. ［30］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123135. DOI: 10.1056/NEJMoa1504627. ［31］ RamosEsquivel A, van der Laat A, RojasVigott R, et al. AntiPD1/antiPDL1 immunotherapy versus docetaxel for previously treated advanced nonsmall cell lung cancer: a systematic review and metaanalysis of randomised clinical trials［J］. ESMO Open, 2017, 2(3): e000236. DOI: 10.1136/esmoopen2017000236. ［32］ Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer: a multicentre, phase 1b study［J］. Lancet Oncol, 2016, 17(3): 299308. DOI: 10.1016/S14702045(15)005446. ［33］ Govindan R, Szczesna A, Ahn MJ, et al. Phase Ⅲ trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous nonsmallcell lung cancer［J］. J Clin Oncol, 2017, 35(30): 34493457. DOI: 10.1200/JCO.2016.71.7629.

[1]	Du Jiahang, Chen Dong, Chen Yaoting. Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2021, 48(9): 572-.
[2]	Su Wenzhen, Lin Yongjie, Wang Zhengyu, Liu Jisong. Clinical effect of local and systemic zoledronic acid in the treatment of giant cell tumor of bone [J]. Journal of International Oncology, 2020, 47(7): 409-413.
[3]	Jin Chenxing, Zhao Yi. Research progress of KRAS mutation in lung adenocarcinoma [J]. Journal of International Oncology, 2020, 47(3): 180-184.
[4]	Wen Jie, Chen Shaoshui . Expression and clinical significance of p53 gene of non-small cell lung cancer [J]. Journal of International Oncology, 2019, 46(2): 102-104.
[5]	Yang Yehuan, Yang Chengwei, Tan Xiaoqing, Gao Xingchun. CRISPR/Cas9 genome editing system and its application in tumor therapy [J]. Journal of International Oncology, 2018, 45(8): 556-560.
[6]	WU Xin, QU Xiu-Juan, ZHANG Ling-Yun. Antitumor therapy of thalidomide [J]. Journal of International Oncology, 2018, 45(8): 490-493.
[7]	LEI Lei, WANG Xian, WANG Xiao-Jia. Research progress of thalidomide in usual nonhematologic malignancies [J]. Journal of International Oncology, 2016, 43(8): 711-714.
[8]	Zhou Yinjie, Xiang Mingfei, Li Tao. Application of big medical data in cancer diagnosis and treatment [J]. Journal of International Oncology, 2016, 43(1): 75-78.
[9]	YUE Li-Juan, HOU Xin-Li, XUE Hui, XUE Ling, GAO Xiang, SHEN Yong, YUAN Liang, ZHANG Jing-Jing, ZHU Hong-Cai. Pemetrexed in combination with cisplatin in the treatment of advanced breast cancer application [J]. Journal of International Oncology, 2014, 41(7): 545-548.
[10]	FANG Jin-Mei, WANG Fan. Application of image-guided adaptive radiation therapy in lung cancer [J]. Journal of International Oncology, 2014, 41(12): 912-914.
[11]	SU Ke-Li, YIN Lin-Lin, LI Jing. Anti-tumor effects of statins [J]. Journal of International Oncology, 2013, 40(5): 342-344.
[12]	TIAN Yong-Li, XIA Ning-Jun. Diagnosis and treatment of peritoneal metastasis of gastric cancer [J]. Journal of International Oncology, 2012, 39(10): 765-769.